{"analyses":[{"ciLowerLimit":"-9.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.0","estimateComment":"Risk difference (% Arm A - Arm B) based on Cochran-Mantel-Haenszel test with adjustment for randomization stratification factors as recorded in IXRS.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.7340","paramType":"Risk Difference (RD)","paramValue":"-1.3","statisticalComment":"Based on Cochran-Mantel-Haenszel test with adjustment for randomization stratification factors as recorded in IXRS.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"130"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"155"}],"units":"Participants"}],"description":"IRC-assessed overall response rate (ORR) including complete response (CR), CR with incomplete blood count recovery (CRi) nodular PR (nPR), and Partial Response (PR)","groups":[{"description":"Acalabrutinib 100 mg orally twice a day","id":"OG000","title":"Arm A: Acalabrutinib Monotherapy"},{"description":"Idelalisib+Rituximab or Bendamustine + Retuximab","id":"OG001","title":"Arm B: Investigator's Choice"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-treat population including all randomized participants","reportingStatus":"POSTED","timeFrame":"Investigator assessments were done from randomization date until date of death or date of exit from study or data cut off date on 03Sep2021, whichever came first, up to 53 months of follow-up.","title":"Investigator Assessed Overall Response Rate (ORR) Per IWCLL 2008 Criteria Based on Data Cutoff 03 September 2021","type":"SECONDARY","unitOfMeasure":"Participants"}